KUALA LUMPUR, Oct 21 (Bernama) -- Angelini Pharma, part of the privately owned Angelini Industries, and Cureverse Inc, an early-stage research and development company, announced they entered into an exclusive global option agreement for the development and commercialisation of Cureverse’s innovative brain health asset CV-01.
Under the terms of the agreement, Angelini Pharma will lead all the development efforts for CV-01 and, following an initial option period, will have the right to obtain the global exclusive development and commercialisation licence for the compound outside of the Republic of Korea, China, Hong Kong, Macau and Taiwan.
“Our strategic collaboration with Cureverse further strengthens Angelini Pharma’s position as an emerging leader in brain health.
“Through the development of CV-01 and potentially other compounds, we aim to provide much-needed solutions for people living with brain health conditions across the world,” said Angelini Pharma Chief Executive Officer (CEO), Jacopo Andreose in a statement.
Meanwhile, Cureverse Inc CEO, Sung Jin Cho said: “Our research has unveiled the remarkable potential of CV-01 to transform the landscape of brain health, from epilepsy to Alzheimer’s and Parkinson’s diseases. We are truly delighted to be partnering with Angelini Pharma on this journey.
“Their deep therapeutic expertise and commitment to brain health perfectly align with our vision. Together, we are not just developing a treatment, we are paving the way for a future where patients with neurological conditions have access to truly life-changing therapies,” he added.
Cureverse will receive an upfront payment and will also be eligible to receive additional payments upon pre-defined development and commercial milestones of up to approximately US$360 million, as well as tiered royalties on post-approval net sales. (US$1=RM4.29)
CV-01 is a novel and innovative investigational compound that activates protective pathways regulated by the nuclear factor erythroid 2-related factor 2 (Nrf2) and has a strong potential to be a medication with disease-modifying properties across a range of brain health disorders, including epilepsy.
Being developed by Cureverse for Alzheimer’s disease, CV-01 is an investigational compound currently undergoing a Phase 1 clinical trial in the Republic of Korea.
-- BERNAMA
No comments:
Post a Comment